1-9 of 9
embolic protection devices
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Katja Weisel, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo
Journal: Blood
Blood (2019) 134 (Supplement_1): 3480.
https://doi.org/10.1182/blood-2019-122232
Published: 2019
Journal Articles

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Ann Forslund, PhD, Hao Tang, Chunzhe Duan, Mihaela Popa-McKiver, PhD, James R. Berenson, MD, Michael Robbins, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1853.
https://doi.org/10.1182/blood-2019-128760
Published: 2019
Journal Articles

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Arafat Ali Farooqui, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Saad Farooqi, MD, Maimoona Khan, MBBS, Aqsa Ashraf, MD, Ahmad Anjum, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhammad Junaid Tariq, MD, Faiz Anwer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5546.
https://doi.org/10.1182/blood-2019-121999
Published: 2019
Journal Articles

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Arafat Ali Farooqui, MD, Ahmad Anjum, MD, Muhammad Saad Farooqi, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Aqsa Ashraf, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Junaid Tariq, MD, Faiz Anwer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5548.
https://doi.org/10.1182/blood-2019-122395
Published: 2019
Journal Articles

Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma

Nikhita Gadi, MDMSc, Linda Schmidt, RN, Jaeil Ahn, PhD, Tianmin Wu, MS, Scott D. Rowley, MD, Elli Gourna Paleoudis, PhD, Michele L. Donato, MD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, David S. Siegel, Noa Biran, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3141.
https://doi.org/10.1182/blood-2019-129504
Published: 2019
Journal Articles

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Mitsuo Hori, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD PhD, Shigeki Ito, MD PhD, Junya Kuroda, MD PhD, Mihaela Popa-McKiver, PhD, Ying-Ming Jou, Suresh G. Shelat, PhD, Masafumi Miyoshi, Kenshi Suzuki, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3260.
https://doi.org/10.1182/blood-2018-99-116225
Published: 2018
Journal Articles

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study

Sundar Jagannath, MD, Jesus G. Berdeja, MD, Robert M Rifkin, MD, Craig E. Cole, MD, Michael Alan Thompson, MD PhD, Ravi Vij, MBBS, Mihaela Popa-McKiver, PhD, Rao Saleem, Oumar Sy, PhD, William Bensinger, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1991.
https://doi.org/10.1182/blood-2018-99-112077
Published: 2018
Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Katja Weisel, MD, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Ashlee Espensen, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2288.
https://doi.org/10.1182/blood-2018-99-112080
Published: 2018
Journal Articles

Molecular Analysis of Rh Transcripts and Polypeptides From Individuals Expressing the D VI Variant Phenotype: An RHD Gene Deletion Event Does Not Generate All D VI ccEe Phenotypes

Neil D. Avent, Wendy Liu, Jeff W. Jones, Marion L. Scott, Douglas Voak, Martin Pisacka, Julie Watt, Anne Fletcher
Journal: Blood
Blood (1997) 89 (5): 1779–1786.
https://doi.org/10.1182/blood.V89.5.1779
Published: 1997